First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations
NCT06043817
This study is recruiting at 9 US sites in 7 states, according to its ClinicalTrials.gov record last updated .
Summary
Study STX-721-101/PFL-721CI101 is an open label, Phase 1/2 study evaluating the safety, tolerability, pharmacokinetic (PK) exposure, and preliminary antitumor activity of STX-721/PFL-721 in participants with non-small cell lung cancer (NSCLC) carrying EGFR or HER2 exon 20 insertion (ex20ins) mutations.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Non-Small Cell Lung Cancer
- NSCLC
- EGFR/HER2 Exon 20 Insertion Mutation
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Pierre Fabre Medicament
- Last updated on ClinicalTrials.gov
- September 2, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 3
- City of Hope · Duarte, CA
- City of Hope · Huntington Beach, CA
- City of Hope · Irvine, CA
North Carolina · 1
- Levine Cancer Institute - Charlotte · Charlotte, NC
Pennsylvania · 1
- Thomas Jefferson University Research Facility · Philadelphia, PA
Tennessee · 1
- SCRI Oncology Partners - PPDS · Nashville, TN
Texas · 1
- University of Texas MD Anderson Cancer Center · Houston, TX
Utah · 1
- University of Utah - Huntsman Cancer Institute - PPDS · Salt Lake City, UT
Virginia · 1
- NEXT Virginia · Fairfax, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.